Portal:CPTAC
From WikiPathways
Current revision (09:21, 6 October 2019) (view source) |
|||
| (4 intermediate revisions not shown.) | |||
| Line 9: | Line 9: | ||
}} | }} | ||
| - | <div style="float:left; width: | + | <div style="float:left; width:73%"> <!-- This width add to the the margin below to equal 99% --> |
| + | |||
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
|<!-- TITLE OF BOX --> | |<!-- TITLE OF BOX --> | ||
| Line 22: | Line 23: | ||
</div> | </div> | ||
| - | <div style="float:right; width: | + | <div style="float:right; width:26%"> <!-- This margin should be right of the above --> |
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 32: | Line 33: | ||
{{FULLPAGENAME}}/Featured | {{FULLPAGENAME}}/Featured | ||
|<!-- FOOTER LINK --> | |<!-- FOOTER LINK --> | ||
| + | }} | ||
| + | |||
| + | {{{{FULLPAGENAME}}/box-normal | ||
| + | |<!-- TITLE OF BOX --> | ||
| + | <big>''Assay Portal''</big> | ||
| + | |<!-- EDIT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | |<!-- CONTENT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | | | ||
}} | }} | ||
| Line 54: | Line 65: | ||
}} | }} | ||
</div> | </div> | ||
| + | |||
| + | [[Category:Portals]] | ||
Current revision
CPTAC Pathways
Welcome to the CPTAC Pathway PortalThis portal highlights pathway content relevant to the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The National Cancer Institute, part of the National Institutes of Health, announced the launch of a Clinical Proteomic Tumor Analysis Consortium in August 2011. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer. To achieve this goal in a scientifically rigorous manner, the NCI launched CPTAC to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public. The pathways included in this portal have been organized into classic cancer hallmark categories, based on the different biological capabilities acquired during the multistep development of human tumors. To read more, see Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011. | 
|
Cancer Hallmark Categories
| Sustaining proliferative signaling
ErbB signaling (Homo sapiens) Image does not exist ErbB signaling | Evading growth suppressors
Retinoblastoma gene in cancer (Homo sapiens) Image does not exist Retinoblastoma gene in cancer | Activating invasion and metastasis
Integrin-mediated cell adhesion (Homo sapiens) Image does not exist Integrin-mediated cell adhesion |
| Enabling replicative immortality
ncRNAs involved in STAT3 signaling in hepatocellular carcinoma (Homo sapiens) Image does not exist ncRNAs involved in STAT3 signaling in hepatocellular carcinoma | Inducing angiogenesis
Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors (Homo sapiens) Image does not exist Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors | Resisting cell death
PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer (Homo sapiens) Image does not exist PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer |
| Deregulating cellular energetics
Target of rapamycin signaling (Homo sapiens) Image does not exist Target of rapamycin signaling | Genome instability and mutation
DNA mismatch repair (Homo sapiens) Image does not exist DNA mismatch repair | Tumor promoting inflammation
IL6 signaling (Homo sapiens) Image does not exist IL6 signaling |
| Avoiding immune destruction
Type II interferon signaling (Homo sapiens) Image does not exist Type II interferon signaling | Therapeutics
NRF2-ARE regulation (Homo sapiens) Image does not exist NRF2-ARE regulation |
Featured Pathways
|
Image does not exist PDGFR-beta pathway Zhang, et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer |
| View featured pathways |
| List of all pathways for this portal |
Assay Portal
CPTAC also includes an Assay Portal to widely disseminate highly characterized proteomic assays to the global research community, with access to SOPs, reagents, and assay characterization/validation data
Resources
- Over 2400 protein and peptide assays: Browse assays
- Over 750 antibodies and antigen targets: Browse antibodies
- Hundreds of terabytes of data sets: Browse data
Learn how they incorpated WikiPathways images with custom links on their site.
Pathway Curation
On this page you see rotating displays of hallmark and featured pathways. Where did these pathways come from? They came from people like you! The CPTAC set of pathways can be edited, fixed and added to using the pathway drawing and annotation tools here at WikiPathways.
Getting Started
- Introduction to WikiPathways (slides)
- WikiPathways Overview or New Contributor Quickstart
- General help pages
- CPTAC Workshop Exercises
Resources
- Learn more about CPTAC
- Pathway analysis
- Cytoscape and the WikiPathways app
- PathVisio and the WikiPathways plugin
Curation projects
- Curating Hallmark Pathways -- How to
- Example: construction of Pathways in Renal Cancer
- Contact Alex Pico if interested in curating, adding or using CPTAC pathways, [email protected]
